Prospects of immunotherapy of MHC class I-deficient tumours

Folia Biologica

Volumn 49, Issue 3, 2003, Pages 95-99

  Bubeník, Jan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA VACCINE; TRICHOSTATIN A; TUMOR VACCINE; VIRUS VACCINE;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; DRUG MECHANISM; EDITORIAL; GENE ACTIVATION; HUMAN; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHUMAN;

EID: 0037710132     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Editorial

References (44)

1. Algarra, I., Collado, A., Garrido, F. (1997) Altered MHC class I antigens in tumors. Int. J. Clin. Lab. Res. 27, 95-102.
2. Alimonti, J., Zhang, Q.J., Gabathuler, R., Reid, G., Chen, S. S., Jefferies, W. A. (2000) TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 18, 515-520.
3. Balkwill, F. R., Stevens, M. H., Griffin, D. B., Thomas, J. A., Bodmer, J. G. (1987) Interferon gamma regulates HLA-D expression on solid tumors in vivo. Eur J. Cancer Clin. Oncol. 23, 101-106.
4. Boehm, U., Klamp, T., Groot, M., Howard, J. C. (1997) Cellular responses to interferon γ. Annu. Rev. Immunol. 15, 749-795.
5. Bubeník, J. (2002) Animal models for development of therapeutic HPV16 vaccines (Review). Int. J. Oncol. 20, 207-212.
6. Bubeník, J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol. 14, 593-597.
7. Bubeník, J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Vonka, V. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
8. Campoli, M., Chang, C.-C., Ferrone, S. (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20, A40-A45.
9. de Smet, C., de Backer, O., Faraoni, I., Lurquin, C., Brasseur, F., Boon, T. (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 93, 7149-7159.
10. Ehtesham, M., Samoto, K., Kabos, P., Acosta, F. L., Gutierrez, M. A. R., Black, K. L., Yu, J. S. (2002) Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther. 9, 925-934.
11. Falk, C. F., Noessner, E., Weiss, E. H., Schendel, D. J. (2002) Retaliation against tumour cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res. 62, 480-487.
12. Fromm, S. V., Ehrlich, R. (2001) IFN-γ affects both the stability and the intracellular transport of class I MHC complexes. J. Interferon Cytokine Res. 21, 199-208.
13. Fruh, K., Yang, Y. (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 11, 76-81.
14. Garbi, N., Tiwari, N., Momburg, F., Hämmerling, G. J. (2003) A major role for tapasin as a stabilizer of the TAP peptide transporter and consequences for MHC class I expression. Eur. J. Immunol. 33, 264-273.
15. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., Stan, P. L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
16. Hicklin, D. J., Marincola, E M., Ferrone, S. (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186.
17. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-963.
18. Imboden, M., Murphy, K. R., Rakhmilevich, A. L., Neal, Z. C., Xiang, R., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. (2001) The level of MHC class expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res. 61, 1500-1507.
19. Indrová, M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
20. - tumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
21. - tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
22. Jäger, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jäger, D., Oesch, F., Knuth, A. (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142-147.
23. Kakuta, S., Tagawa, Y.-I., Shibata, S., Nanno, M. (2002) Inhibition of B16 melanoma experimental metastasis by interferon γ through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105, 92-100.
24. Kallfelz, M., Jung, D., Hilmes, C., Knuth, A., Jaeger, E., Huber, C., Seliger, B. (1999) Induction of immunogenicity of a human renal cell carcinoma cell line by TAP1-gene transfer. Int. J. Cancer 81, 125-133.
25. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., Schreiber, R. D. (1998) Demonstration of an interferon γ-dependent tumour surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-75561.
26. Khong, H. T., Restifo, N. P. (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005.
27. Levitsky, H. I., Lazenby, A., Hayashi, R. J., Pardoll, D. M. (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224.
28. Lu, Y., Yamagishi, N., Koshita, Y., Fujiwara, H., Sato, Y., Fujii, S., Takahashi, M., Sato, T., Kato, J., Yamagishi, H., Niitsu, Y. (2001) Administration of subtumor regression dosage of TNF-α to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther. 8, 499-507.
29. Mikyšková, R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV 16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
30. Mikyšková, Bieblová, R., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003) Local IFN-γ therapy of HPV16-associated tumours. Folia Biol. (Praha) 49, 26-32.
31. Moreau, P., Mouillot, G., Rousseau, P., Marcon, C., Dausset, J., Carosella, E.D. (2003) HLA-G gene repression is reversed by demethylation. Proc. Natl. Acad. Sci. USA 100, 1191-1196.
32. Nanni, P., Rossi, I., De Giovanni, C., Landuzzi, L., Nicoletti, G., Stoppacciaro, A., Parenza, M., Colombo, M. P., Lollini, P.-L. (1998) Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58, 1225-1230.
33. Primeau, M., Gagnon, J., Momparler, R. L. (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 103, 177-184.
34. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88, 100-108.
35. Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampe, R., Huber, C. (1998) Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol. 28, 122-133.
36. Seliger, B., Maeurer, M. J., Ferrone, S. (2000) Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455-464.
37. Skoskiewicz, M. J., Calvin, R. B., Schneeberger, E. E., Russel, P. S. (1985) Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J. Exp. Med. 162, 1645-1664.
38. Šmahel, M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F. (2001) Metastatic MHC class 1 negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
39. Tait, B. D. (2000) HLA class I expression on human cancer cells. Implications for effective immunotherapy. Human Immunol. 61, 158-1165.
40. Tatake, R. J., Zeff, R. A. (1993) Regulated expression of the major histocompatibility complex class I genes. Proc. Soc. Exp. Biol. Med. 203, 405-417.
41. Vilček, J. (2003) Novel interferons. Nat. Immunol. 4, 8-9.
42. Weber, J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J., Rosenberg, S. A. (1994) Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54, 1766-1771.
43. Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., Ferrant, A. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multi-center phase II study in elderly patients. J. Clin. Oncol. 18, 956-962.
44. Yoon, S. J., Lee, J. C., Kang, J. O., Lee, S. G., Heo, D. S. (2001) Anti-tumor effect associated with down-regulation of MHC class I antigen after co-transfection of GM-CSF and IFNγ genes in CT26 tumor cells. Anticancer Res. 21, 4031-4040.